NIH Weekly Funding Opportunities and Policy Notices

Tuesday, March 19, 2024 - 8:06am
Funding Opportunity RFA-RM-24-004 from the NIH Guide for Grants and Contracts. The NIH Directors Transformative Research Award Program supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. To support innovative and novel research across the vast NIH mission, individuals from diverse backgrounds (including those from underrepresented groups; see Notice of NIHs Interest in Diversity) and from the full spectrum of eligible institutions in all geographic locations are encouraged to apply to this Notice of Funding Opportunity. Applications in all topics relevant to the broad mission of NIH are welcome in all topic areas relevant to the broad mission of NIH, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Directors Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. Towards the objective of funding the best possible science, the Office of Strategic Coordination and the Center for Scientific Review are piloting a process for initial peer review of applications received in response to this FOA in which the identity of the investigators and institutions are withheld until the last phase of review. Instructions for anonymizing components of the application are given in Section IV and must be carefully followed. A description of the review process is given in Section V.
Tuesday, March 19, 2024 - 12:14am
Funding Opportunity RFA-MH-25-110 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this NOFO. The data archives will use appropriate standards to describe the data, but the creation of such standards is not part of this NOFO. A goal of this program is to advance research by creating a community resource data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research.
Tuesday, March 19, 2024 - 12:13am
Funding Opportunity RFA-RM-24-005 from the NIH Guide for Grants and Contracts. The NIH Director's Early Independence Award supports rigorous and promising junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. To support innovative and novel research across the vast NIH mission, individuals from diverse backgrounds (including those from underrepresented groups; see Notice of NIHs Interest in Diversity) and from the full spectrum of eligible institutions in all geographic locations are encouraged to apply to this Notice of Funding Opportunity. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's Early Independence Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.
Tuesday, March 19, 2024 - 12:10am
Funding Opportunity RFA-NS-24-017 from the NIH Guide for Grants and Contracts. Reissue: RFA-NS-21-024: The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study). Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical trial to answer key questions about the function or final design of a device. As part of the BRAIN Initiative, NIH has initiated a Public-Private Partnership Program (BRAIN PPP) that includes agreements (Memoranda of Understanding, MOU) with a number of device manufacturers willing to make such devices available, including devices and capabilities not yet market approved but appropriate for clinical research. In general it is expected that the devices' existing safety and utility data will be sufficient to enable new IRB NSR or FDA IDE approval without need for significant additional non-clinical data. For more information on the BRAIN PPP, see http://braininitiative.nih.gov/BRAIN_PPP/index.htm
Monday, March 18, 2024 - 10:57am
Funding Opportunity RFA-AG-25-013 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO) invites applications to develop and maintain a (NSC3). The goal of the NSC3 is to provide logistical and organization support of the NSC. Applicants should be familiar with Nathan Shock Centers (NSC) activities, but they do not need to be part of an NSC. Major activities of the proposed NSC3 will include improving visibility of the NSC nationally and internationally, improving collaboration and coordination among NSC, enhancing NSC training activities, facilitating the sharing of resources, and interacting with NIA and NSC to develop strategies and plans for further development. The successful application will include a plan to improve transparency and the interactions of NSC with the research community. It should also leverage existing bioinformatics resources. The NSC3 director will be a participant in the NIA's Research Centers Collaborative Network.
Monday, March 18, 2024 - 10:56am
Funding Opportunity RFA-AG-25-012 from the NIH Guide for Grants and Contracts. This NOFO invites applications for the Nathan Shock Centers of Excellence in Basic Biology of Aging (NSC). These Center grants will provide funding for leadership, training, research, and outreach activities that will increase and disseminate scientific knowledge in areas supported by the NIA's Division of Aging Biology.
Monday, March 18, 2024 - 9:56am
Funding Opportunity PAR-24-162 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently outlined by the NIH Office of AIDS Research (OAR) in NOT-20-018, UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding, scientific priorities. Potential topics could address multiple overarching priorities. These include elucidation of unique pathophysiological mechanisms contributing to HIV comorbidities, coinfections, and complications (CCCs) affecting organs, tissues, and processes within the mission of the NIDDK. Likewise, interrogations into biological mechanisms underlying HIV reservoirs in NIDDK-relevant tissues are important for developing strategies for long-term viral suppression or eradication. Finally, health-impeding social determinants of health may affect CCCs or viral reservoirs within NIDDK's mission through multiple pathways.
Monday, March 18, 2024 - 9:43am
Funding Opportunity RFA-MH-25-120 from the NIH Guide for Grants and Contracts. NIMH seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions that utilize lethal means safety strategies to reduce suicide risk in healthcare and community settings. Behavioral health clinics that incorporate lethal means counseling into their programming have been associated with significant reductions in suicide attempts and death. Yet, the field is lacking strong evidence on the effectiveness of these strategies tested in healthcare and community settings. Pilot effectiveness research will advance knowledge regarding optimization strategies, therapeutic change mechanisms, and inform decisions about whether further effectiveness testing is warranted. The research will provide preliminary evidence on the extent to which lethal means safety interventions more optimally lead to improved safety (e.g., number/percent of firearms safely stored, overdose injury codes for an individual) and lower suicide risk. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitively test the effectiveness of the intervention.
Sunday, March 17, 2024 - 11:40pm
Notice NOT-RM-24-008 from the NIH Guide for Grants and Contracts
Sunday, March 17, 2024 - 11:09pm
Funding Opportunity RFA-NS-25-014 from the NIH Guide for Grants and Contracts. "Fluctuating cognition can occur in many types of dementia and is a core clinical feature of Dementia with Lewy Bodies. Cognitive fluctuations can last from seconds to days, are unpredictable (e.g., do not just occur in the evenings, as with sun-downing), and are associated with poor daily functioning for the patient. A number of small studies have suggested that cognitive fluctuations in subjects with dementia may be related to epileptiform discharges and impaired oscillatory activity on EEG, but it is not clear that these are the only factors involved in patient populations that often experience dysautonomia, orthostasis, and sleep disturbances. The etiology of cognitive fluctuations may be multi-factorial and may vary in different dementia populations. Understanding the physiology related to cognitive fluctuations is a critical next step to the development of treatment approaches and improving quality of life for these patients. This initiate would encourage research that will better characterize the physiology responsible for cognitive fluctuations in ADRD populations. Given their variable appearance and time course, it is anticipated that wearable digital devices will be important for capturing fluctuations in a timely fashion, and applicants should consider incorporating those device(s) capable of acquiring the relevant data to support the hypothesized mechanism(s). Applicants may focus on assessing multiple mechanisms in a specific ADRD population, or may chose to compare mechanisms across multiple types of ADRDs. "
Friday, March 15, 2024 - 12:53am
Notice NOT-CA-24-035 from the NIH Guide for Grants and Contracts
Friday, March 15, 2024 - 12:33am
Notice NOT-HD-24-010 from the NIH Guide for Grants and Contracts
Friday, March 15, 2024 - 12:33am
Notice NOT-HD-24-009 from the NIH Guide for Grants and Contracts
Thursday, March 14, 2024 - 11:53pm
Notice NOT-HS-24-010 from the NIH Guide for Grants and Contracts
Thursday, March 14, 2024 - 8:07am
Funding Opportunity RFA-DA-25-005 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. This NOFO will also support research on the discovery of novel modulatory probes/tools that can advance our knowledge of the regulatory mechanisms by which neuroimmune interactions contribute to HIV and substance use disorder comorbidity.
Thursday, March 14, 2024 - 8:06am
Funding Opportunity RFA-DA-25-004 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. This NOFO will also support research on the discovery of novel modulatory probes/tools that can advance our understanding of the regulatory mechanisms by which neuroimmune interactions contribute to HIV and substance use disorder comorbidity.
Thursday, March 14, 2024 - 12:46am
Funding Opportunity RFA-OD-24-014 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support collaborative, transdisciplinary, translational research projects which advance exceptionally promising, chemically complex botanical and other natural products relevant to dietary supplements towards highly informative clinical trials of their effects on quantitative, objective measures of human resilience. Dynamic, synergistic interactions among the range of experts required to ensure rigor in all aspects of this research will be supported by a multi-PD/PI team collaborating on a single set of integrated specific aims, culminating in data on optimal parameters for a future proposed clinical efficacy trial, as well as the development and validation of other critical knowledge and methods for interpretation of such a trial, such as clinical assessment of the engagement of an outcome-relevant target. Enhancing workforce and institutional capacity to conduct future rigorous, transdisciplinary research on chemically complex natural products must be built into the plans for research and for enhancing diverse perspectives. Achievement of the RM1 specific aims is expected to provide a strong foundation for a future highly informative clinical efficacy trial of the effects on resilience of a chemically complex natural product. This NOFO is one component of the Consortium Advancing Research on Botanicals and Other Natural Products (CARBON) Program. Other components of this Program include RFA-AT-24-008, Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01) and RFA-AT-24-007, Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data (R24).

Pages